Latest news

• Pfizer’s flat sales focus investor attention on M&A

  Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for

• Pfizer files third-gen ALK inhibitor for lung cancer

  Pfizer has filed for approval of its third-generation ALK inhibitor lorlatinib, a follow-up to its first-generation Xalkori product which is facing increasing competition. ... Lorlatinib was developed by Pfizer scientists with the specific goal of

• Roche gets FDA OKs for Alecensa and Zelboraf

  Roche’s oncology business unit chalked up two FDA approvals this week for its new ALK inhibitor Alecensa in first-line lung cancer and BRAF inhibitor Zelboraf in a rare blood ... That allows Roche’s drug to take on Pfizer’s drug - as well as

• Novartis gets first-line approval for Xalkori challenger in EU

  Novartis' Zykadia can now compete head-to-head in Europe against Pfizer's Xalkori after winning approval as a first-line therapy for ALK-positive non-small cell lung cancer (NSCLC). ... It is only the second ALK inhibitor approved for first-line use in

• Novartis' Zykadia claims US approval for first-line lung cancer

  The approval is good news for Novartis, although its key competitor in the coming period will not be so much Xalkori as Roche's ALK inhibitor Alecensa (alectinib), which bested ... Meanwhile additional competition in the ALK inhibitor market is looming